Background {#Sec1}
==========

Circulatory shock is a life-threatening condition affecting about one-third of patients admitted to the intensive care unit (ICU) \[[@CR1], [@CR2]\]. Regardless of the underlying pathophysiological mechanisms, the hallmark of shock states is altered tissue perfusion, which if not rapidly corrected leads to organ dysfunction and death \[[@CR3], [@CR4]\]. Recent data have highlighted the prognostic importance of microcirculatory abnormalities in patients with shock using noninvasive bedside techniques, such as sublingual video-microscopy \[[@CR5]--[@CR8]\]. The hallmark of these alterations is decreased capillary density, and microvascular blood flow with increased heterogeneity of perfusion \[[@CR9], [@CR10]\]. Interestingly, these microcirculatory abnormalities are not explained by routinely measured global macro-hemodynamic variables, making it attractive to assess them directly \[[@CR11], [@CR12]\].

The microcirculation can also be studied by evaluating the response generated by a hypoxic stress event, such as during a transient vascular occlusion test (VOT) \[[@CR7], [@CR8]\]. Near-infrared spectroscopy (NIRS) or laser Doppler techniques can be used to indirectly or directly evaluate a transient increase in flow after a VOT \[[@CR13]--[@CR15]\]. Studies using these techniques have shown that endothelial reactivity is impaired in sepsis and is associated with organ dysfunction and outcome \[[@CR16], [@CR17]\]. However, VOTs are not easily standardized (duration of occlusion and/or tissue oxygen saturation \[StO~2~\] reached) \[[@CR16], [@CR18]\]. In addition, VOTs may alter local metabolism \[[@CR19]\]. Alternative methods to evaluate microvascular recruitment are, therefore, of interest.

Local heating of the skin may represent an alternative means of evaluating microvascular reactivity. Skin laser Doppler (SLD) (also known as laser Doppler flowmetry) can be used to assess skin blood flow (SBF) during a thermal challenge \[[@CR14]\]. This technique uses an optical fiber to direct light from a low-power laser source to the skin and to collect the back-scattered light. The shift in light wavelength is proportional to the red blood cell velocity in the studied skin area, providing a noninvasive measurement of SBF expressed as arbitrary perfusion units (PUs) \[[@CR20]\]. New SLD flow probes can heat the explored tissue in a controlled way, making it possible to perform a dynamic test of capillary reactivity by increasing local temperature \[[@CR14]\]. However, there are no published data evaluating this test in patients with circulatory shock.

We hypothesized that reactivity of the skin microcirculation, evaluated as the skin blood flow ratio, during a thermal challenge would be impaired in patients with circulatory shock. We also assessed whether these alterations could be explained by other hemodynamic parameters and were correlated with patient outcome.

Methods {#Sec2}
=======

This prospective, observational study was conducted in our 35-bed Department of Intensive Care. Institutional Ethical Committee approval was obtained, and informed consent was obtained from each participant or the next of kin.

Protocol {#Sec3}
--------

To assess the most appropriate probe position for an SLD thermal challenge, we first studied 18 healthy volunteers. They were comfortably seated in a quiet, temperature-controlled room for at least 15 min before each experiment. Heart rate, respiratory rate and hemoglobin saturation were evaluated noninvasively by pulse oximetry using a Siemens SC 9000 monitor (Siemens, Erlangen, Germany). Noninvasive measurements of mean arterial pressure (MAP) were taken in the opposite arm to that used for the SLD blood flow measurements.

We then studied, in 2013, a cohort of 29 critically ill adult patients admitted with a diagnosis of circulatory shock, defined as the need for norepinephrine infusion to maintain a MAP of at least 65 mmHg, associated with an altered mental status, acute oliguria defined as a urine output \< 0.5 ml/Kg/h or an arterial lactate level \> 2 mmol/L \[[@CR4]\]. Screening of ICU admissions, collection of data and SLD measurements were performed by doctors not involved in patient management. All SLD measurements were taken as soon as possible after completion of initial resuscitation, i.e., when an adequate arterial pressure for that patient had been reached (determined by the treating physician), and norepinephrine doses had been stable for 1 h. A second SLD measurement was taken, when possible, 48 h after the first measurement.

Having analyzed the results from our first patient cohort, we repeated the study in a second, confirmatory cohort of critically ill patients with circulatory shock (using the same definition) admitted in 2015. Patients were evaluated by an investigator who had not been involved in the initial study and at just one time point during the first day of hospitalization after initial resuscitation.

We collected demographic and clinical data on admission and classified patients as having sepsis or not, based on standard criteria \[[@CR21]\]. At the time of each SLD measurement, we collected all available hemodynamic and respiratory data from ongoing patient monitors and recorded the central body temperature. We also collected biochemical and laboratory data from clinical records, including the most recent blood gas analysis. The APACHE II score \[[@CR22]\] was calculated using the worst data during the first 24 h in the ICU. The sequential organ failure assessment (SOFA) score \[[@CR23]\] was calculated from the data present at the time of the SLD measurements. Patients were grouped according to ICU outcome (dead or alive) for further analysis.

Skin laser Doppler measurements {#Sec4}
-------------------------------

All SLD measurements were taken using the PeriFlux System 5000 monitor (Perimed, Jarfalla, Sweden), and data were continuously collected (PeriSoft software 2.5.5; Perimed) for further analysis. For the thermal challenge, a small angled thermostatic SLD probe 457 (Perimed) with 0.25 mm fiber separation was used. This probe also allows skin temperature measurement at site of application. The SLD machine emits a beam of laser light with a wavelength of 780 nm that allows skin evaluation at a depth of 0.5--1 mm. The initial skin temperature was measured with the thermostatic probe prior to each measurement. In the healthy volunteers, the probe was placed on the skin of the volar face of the proximal forearm and on the palm of the same arm. In the patients, the SLD probe was placed on the forearm without the arterial line. The probe was kept in position using the double-sided tape provided with the SLD monitor. All participants were asked to abstain from any activity during the study period to prevent any possible artifacts in the recorded signals \[[@CR13]\].

To limit differences between subjects in the basal temperature, SBF was recorded at a local skin temperature of 37 °C allowing for at least three minutes of stabilization. Thereafter, a thermal challenge was performed by increasing the probe temperature abruptly (0.1 °C/s) from 37 to 43 °C. After 9 min at 43 °C, the SBF was recorded (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We chose to increase the temperature to 43 °C, because our preliminary experience indicated that using lower thresholds (39 °C or 41 °C) reduced the amplitude of the response, making it more difficult to detect potential differences. We calculated the SBF ratio (SBF obtained at 43 °C/SBF obtained at 37 °C) as a simple measure of microvascular reactivity in the explored area.

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed using SPSS 22.0 (IBM, New York, NY) software. Variables were assessed for normality of distribution using skewness and kurtosis tests and Q--Q plots. Continuous variables are presented as means ± standard deviations or median values with percentiles (25--75%) depending on the presence or absence of normality. Categorical data are presented as numbers of events and percentages. Repeated measurements were compared using a paired Student's *t* test or Wilcoxon signed rank test, as appropriate. Comparisons between different cohorts were made using an unpaired *t* test or Mann--Whitney *U* test as appropriate. Proportions were compared with a Chi-square test or Fisher's exact test as appropriate. We plotted the sensitivity and specificity using a receiving operating characteristics (ROC) graph, and the area under the curve (AUC) was calculated for the different variables as a measure of their ability to predict mortality. To assess possible explanatory variables correlated with the SBF ratio, we plotted individual data on graphs and calculated the Pearson or Spearman correlation coefficient (*r*) as appropriate. Univariate and multivariate analyses (binary logistic regressions) were performed to identify the ability of different variables to predict ICU mortality, calculating the odds ratios and their respective 95% confidence intervals.

In a post hoc analysis considering that the APACHE II score was directly correlated and the SBF ratio inversely correlated with mortality, we calculated the ratio between the two factors (APACHE II score/SBF ratio) in an attempt to improve their prognostic value.

A two-sided *p* value less than 0.05 was considered as significant for all analyses.

Results {#Sec6}
=======

Healthy volunteers {#Sec7}
------------------

The main characteristics of the volunteers are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Comparisons of measurements taken in the hand and the forearm are shown in Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2. Baseline values of SBF at 37 °C were lower in the forearm than in the hand, but the SBF ratio was higher in the forearm.Fig. 1Comparison of skin blood flow measurements at different temperatures on the forearm and the hand in healthy volunteers. In the right panel, the ratio of skin blood flow obtained between 43 and 37 °C is presented. \**p* \< 0.05 compared with measurements at 37 °C; \#*p* \< 0.05 compared with forearm measurements

Patients: initial cohort {#Sec8}
------------------------

The main demographic and baseline characteristics of the 29 patients are listed in Table [1](#Tab1){ref-type="table"}: 16 (55%) had septic and 13 (45%) cardiogenic shock. Eleven patients died in the ICU (44%). Times from ICU admission until the first measurement were similar in survivors and non-survivors: 6 (4--17) versus 7 (5--14) h (*p* = 0.59). The patients had a similar baseline SBF to the healthy volunteers, but a lower SBF at 43 °C, which resulted in a lower SBF ratio (Table [2](#Tab2){ref-type="table"}). SBF values at baseline and at 43 °C were similar in survivors and non-survivors, but survivors had significantly higher SBF ratios (Table [2](#Tab2){ref-type="table"}). A comparison of the SBF ratios in volunteers, survivors and non-survivors is shown in Fig. [2](#Fig2){ref-type="fig"}.Table 1Main baseline characteristics of patients with circulatory shockVariableInitial cohortConfirmatory cohortTotal (*n* = 29)Survivors (*n* = 18)Non-survivors (*n* = 11)*P*Total (*n* = 35)Survivors (*n* = 17)Non-survivors (*n* = 18)*P*Age (years)67 ± 1164 ± 1271 ± 80.1164 ± 1661 ± 1667 ± 160.30Body mass index (kg/m^2^)26 ± 625 ± 527 ± 80.6628 ± 527 ± 528 ± 50.29Septic shock \[*n* (%)\]16 (55)9 (50)7 (64)0.8228 (80)13 (77)15 (83)0.61Cardiogenic shock \[*n* (%)\]13 (45)9 (50)4 (36)0.827 (20)4 (23)3 (17)0.61Chronic kidney disease \[*n* (%)\]8 (28)7 (39)1 (9)0.118 (23)4 (24)4 (22)1.00Chronic arterial hypertension \[*n* (%)\]20 (69)11 (61)9 (82)0.4111 (31)5 (29)6 (33)0.80Diabetes mellitus \[*n* (%)\]12 (41)7 (39)5 (46)0.7311 (31)5 (29)6 (33)0.80Coronary artery disease \[*n* (%)\]9 (31)5 (28)4 (36)0.698 (23)3 (18)5 (28)0.69Mean arterial pressure (mmHg)75 ± 1373 ± 977 ± 170.5273 ± 972 ± 775 ± 100.28Heart rate (bpm)97 ± 2599 ± 2595 ± 270.6799 ± 22101 ± 2298 ± 220.71Central venous pressure (mmHg)11 (8--12)11 (7--12)11 (9--13)0.289 (7--12)8 (6--11)10 (8--12)0.23Cardiac output (L/min)4.0 (3.4--5.7)\
*n* = 183.8 (3.2--4.7)\
*n* = 114.1 (3.5--6.8)\
*n* = 70.444.8 (3.5--6.3)\
*n* = 324.8 (3.4--6.7)\
*n* = 164.6 (3.6--5.6)\
*n* = 160.68Central temperature (°C)36.8 (36.0--37.5)37.1 (36.2--37.8)36.5 (35.9--37.3)0.1936.9 (36.6--37.5)36.8 (36.6--37.2)37.0 (36.6--37.6)0.71Basal forearm temperature (°C)32.0 (31.1--32.7)32.1 (31.1--32.7)31.4 (30.7--32.7)0.5830.6 (29.1--31.6)30.5 (28.9--31.6)30.7 (30.0--31.8)0.55Central to basal forearm temperature (°C)5.1 (4.2--6.1)5.0 (4.5--6.4)5.0 (4.2--5.6)0.446.5 (5.6--7.6)7.4 (5.2--7.9)6.4 (5.8--7.1)0.54pH7.35 ± 0.077.36 ± 0.067.33 ± 0.090.297.35 ± 0.127.33 ± 0.137.36 ± 0.110.42PCO~2~ (mmHg)38 ± 839 ± 935 ± 80.2237 ± 1140 ± 1435 ± 80.22Lactate (mmol/L)2.4 (1.6--4.8)1.9 (1.5--2.9)3.2 (1.6--6.3)0.351.7 (1.2--2.6)1.6 (1.1--2.7)1.8 (1.3--2.4)0.78Mechanical ventilation \[*n* (%)\]25 (86)15 (83)10 (91)1.0025 (71)10 (59)15 (84)0.11PaO~2~/FiO~2~ ratio192 (132--293)196 (128--310)192 (145--250)0.93166 (124--244)189 (124--247)146 (120--211)0.24Creatinine (mg/dL)1.4 (1.0--1.7)1.4 (0.9--1.6)1.6 (1.0--2.2)0.441.3 (0.8--2.0)1.3 (0.8--1.9)1.2 (0.8--2.1)0.82Total bilirubin (mg/dL)0.9 (0.5--2.1)0.9 (0.5--1.8)1.6 (0.6--2.8)0.300.8 (0.5--2.7)0.8 (0.5--2.7)0.9 (0.5--2.6)0.58Platelets (× 10^3^/µL)163 (92--243)160 (92--243)163 (65--307)0.9352 (13--79)58 (25--108)22 (7--67)0.06Leukocytes (cells × 10^3^/µL)12.4 (8.5--17.7)11.7 (8.2--17.7)12.4 (8.5--17.7)0.9512.0 (8.5--19.9)12.5 (10.4--21.9)10.8 (4.7--17.0)0.16Number of patients receiving sedatives \[*n* (%)\]17 (59)10 (56)7 (64)0.678 (23)4 (24)4 (22)1.00Number of patients receiving opiates \[*n* (%)\]22 (76)14 (78)8 (73)1.007 (20)4 (24)3 (17)0.69APACHE II score26 ± 823 ± 730 ± 80.0326 ± 822 ± 829 ± 6\< 0.01SOFA score10 ± 310 ± 312 ± 30.0410 ± 59 ± 511 ± 40.13Number of patients receiving dobutamine \[*n* (%)\]13 (45)7 (39)6 (54)0.416 (17)2 (24)2 (11)0.40Dobutamine dose at moment of thermal challenge (mcg/Kg/min)0 (0--10)0 (0--5)10 (0--15)0.240 (0--0)0 (0--0)0 (0--0)0.42Norepinephrine dose at moment of thermal challenge (mcg/Kg/min)0.32 (0.11--0.50)0.28 (0.11--0.41)0.43 (0.11--0.84)0.430.12 (0.08--0.55)0.12 (0.07--0.41)0.20 (0.08--0.62)0.36ICU length of stay (days)8.0 (3.5--16.0)8.6 (4.4--16.0)6.5 (2.1--19.6)0.445.3 (3.2--9.0)4.7 (4.0--9.0)6.0 (3.2--8.0)0.70 Table 2Comparison of skin laser Doppler (SLD) variables between volunteers and patients and between survivors and non-survivorsSLD variableHealthy volunteers and initial cohortInitial cohortConfirmatory cohortVolunteers (*n* = 18)Patients (*n* = 29)*P*Survivors (*n* = 18)Non-survivors (*n* = 11)*P*Survivors (*n* = 17)Non-survivors (*n* = 18)*P*Skin blood flow 37 °C (PU)10.3 (8.0--14.2)13.0 (10.1--19.5)0.1613.4 (10.0--21.6)13.0 (10.1--19.5)0.4412.4 (8.0--17.3)15.0 (10.2--19.3)0.44Skin blood flow 43 °C (PU)112.8 (88.0--150.0)36.4 (25.6--76.9)\< 0.0151.8 (25.6--77.2)33.7 (16.5--39.0)0.7657.4 (41.5--71.5)33.1 (21.8--41.6)\< 0.01Skin blood flow ratio11.2 (9.4--13.4)2.6 (2.0--3.6)\< 0.013.2 (2.2--6.2)2.3 (1.7--2.8)\< 0.013.7 (2.9--6.2)2.1 (1.6--2.5)\< 0.01*PU* perfusion units Fig. 2Comparison of the capillary reactivity, evaluated as the skin blood flow ratio, in the healthy volunteers and the patients with circulatory shock (initial and confirmatory cohorts). \**p* \< 0.05 compared with healthy volunteers; \$*p* \< 0.05 compared with survivors

SLD measurements were repeated at 48 h in 20 of the patients. At that time point, the survivors had a somewhat higher SBF ratio than the non-survivors although the differences were not statistically significant \[3.1 (2.4--4.3) vs. 2.3 (1.5--3.1), *p* = 0.08\] (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). The difference in the SBF ratio between T0 and T48 was not significant in survivors or non-survivors (Additional file [1](#MOESM1){ref-type="media"}: Figure S3).

There were no significant correlations between the SBF ratio and any hemodynamic or blood gas-derived variable, administration of vasoactive drugs (Additional file [1](#MOESM1){ref-type="media"}: Figure S4), presence of sepsis (Additional file [1](#MOESM1){ref-type="media"}: Table S3), degree/severity of organ dysfunction (SOFA score), initial forearm temperature or the difference between the central to forearm temperature (Additional file [1](#MOESM1){ref-type="media"}: Figure S5).

The SBF ratio and the APACHE II score had similar ROC AUCs to predict survival (0.73 \[0.55--0.91\] vs. 0.74 \[0.56--0.92\], respectively) (Fig. [3](#Fig3){ref-type="fig"}). There was no significant correlation between the SBF ratio and the APACHE II score (*r* = 0.047, *p* \> 0.05), so that we calculated their combined ratio, which resulted in a larger ROC AUC to predict survival than that for either measure alone (0.90 \[0.79--1.00\], Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Receiver operating characteristic (ROC) curves for the predictive value of the APACHE II score, the skin blood flow (SBF) ratio and the APACHE II/SBF ratio (initial and confirmatory cohorts)

Considering a cutoff ratio of 3 for the SBF ratio, the specificity and sensitivity were 91 and 56%, respectively, to predict survival. Considering a cutoff value of 2 for the SBF ratio, the specificity and sensitivity were 36 and 83%, respectively.

In multivariable analysis, taking into consideration the SOFA score, the blood lactate concentration, the mean arterial pressure, the norepinephrine dose and the presence of sepsis, only the APACHE II score and the SBF ratio were independently correlated with mortality (Additional file [1](#MOESM1){ref-type="media"}: Table S4).

Patients: confirmatory cohort {#Sec9}
-----------------------------

The demographic and baseline characteristics of the 35 patients in the confirmatory cohort are listed in Table [1](#Tab1){ref-type="table"}: 28 had septic (80%) and 7 cardiogenic (20%) shock. Eighteen patients died in the ICU (51%). SBF values at baseline were similar in survivors and non-survivors, but survivors had significantly higher SBF values at 43 °C and larger SBF ratios (Table [2](#Tab2){ref-type="table"}).

There were no significant correlations between the SBF ratio and any hemodynamic or blood gas-derived variable, dose of vasoactive drugs, presence of sepsis (Additional file [1](#MOESM1){ref-type="media"}: Table S3), degree/severity of organ dysfunction (SOFA score), initial forearm temperature or the difference between the central to forearm temperature (all *p* values \> 0.05).

The ROC AUCs to predict survival were 0.85 (0.73--0.98) and 0.77 (0.60--0.94) for the SBF ratio and the APACHE II score, respectively. The ratio between the APACHE II score and the SBF ratio resulted in an ROC AUC to predict survival of 0.91 (0.82--1.00) (Fig. [3](#Fig3){ref-type="fig"}).

Considering a cutoff ratio of 3 for the SBF ratio, the specificity and sensitivity to predict survival were 83 and 71%, respectively. Considering a cutoff value of 2 for the SBF ratio, the specificity and sensitivity for prediction of survival were 50 and 88%, respectively.

Discussion {#Sec10}
==========

In this study, reactivity of the skin microcirculation during a thermal challenge was compromised in patients with circulatory shock, and this impairment was related to outcome. This phenomenon could not be explained by other hemodynamic variables and was independent of regularly used scoring systems, such as the SOFA and the APACHE II score.

As far as we know, this is the first report to assess the skin microvascular reactivity (or vasodilatation) during a thermal challenge in shock patients. Several previous reports have used an ischemic challenge to assess microcirculatory reactivity \[[@CR7]\] and shown that post-occlusive reactive hyperemia is impaired in patients with sepsis and septic shock, and this has been correlated with poor outcomes \[[@CR15]--[@CR17], [@CR24]\]. However, this condition is not pathognomonic of sepsis and is also present in hemorrhagic \[[@CR25]\] and cardiogenic \[[@CR19], [@CR26]\] shock. Our data also show that the degree of impairment in microvascular reactivity during a thermal challenge was similar in septic and cardiogenic shock. Nevertheless, studies in patients with just cardiogenic, septic or hemorrhagic shock may be of interest to further investigate whether the effects of a thermal challenge are indeed similar across different shock etiologies. Our results were not correlated with other regularly used parameters, but this is not surprising considering the considerable previous literature showing dissociation between the macro- and microcirculations \[[@CR11], [@CR12]\].

Importantly, an ischemic challenge can significantly alter local metabolism. Hence, some NIRS-derived variables, such as the descending slope (the rate of decrease in tissue oxygen saturation during a VOT and correlated with tissue oxygen consumption), may be affected by some degree of ischemic preconditioning in the studied tissue, limiting the reproducibility of results over a short time period \[[@CR19]\]. The thermal challenge that we propose allows the SBF to return to baseline within minutes, enabling the test to be repeated in the same area. If there are concerns about alterations in local metabolism, the challenged area is very small (compared to the complete extremity involved during a VOT), so that the test can be repeated in an adjacent area.

The mechanisms underlying a thermal challenge are different to those of an ischemic challenge. As the skin temperature increases, the SBF increases until a maximum plateau value is reached \[[@CR27]--[@CR29]\]. More specifically, an initial short-lived phase of rapid vasodilation, which is neurally driven, is followed by a more gradual but protracted increase in SBF that is dependent on local nitric oxide (NO) production stimulated by endothelial NO synthase \[[@CR27]--[@CR31]\]. Thus, the use of this very simple and noninvasive test may provide an indirect assessment of the local NO pathway. NO plays a major role in the local control of the microcirculation and in its interaction with red blood cells \[[@CR32], [@CR33]\]. It also plays an important role in the pathophysiology of sepsis and septic shock \[[@CR34], [@CR35]\] and of cardiogenic shock \[[@CR36], [@CR37]\]. Interestingly, during endotoxin infusion in healthy volunteers, recruitment of the skin microcirculation through a thermal challenge that involves NO-dependent pathways was impaired, whereas post-occlusive reactive vasodilation was not \[[@CR38]\]. Thus, the worse outcome in patients with shock who had compromised skin microvascular reactivity after the thermal challenge may reflect altered NO pathways. Nevertheless, physiological or basic science studies need to be conducted to verify the role of the NO pathway in our observations.

Two important technical aspects should be discussed further: the position of the probe on the forearm and the duration of the thermal challenge. Intuitively, the skin area used to perform SLD with a thermal challenge should have the highest potential recruitment even if the baseline SBF is relatively low. SLD studies have shown that the cutaneous microcirculation in healthy volunteers is very heterogeneous with lower blood flow values in the forearm than in the palm and lower values in the metacarpal spaces than in the fingertips \[[@CR14], [@CR39]\]. Similar observations have been made for other areas of the body, such as the torso, feet and face, and this heterogeneity has been confirmed by other techniques evaluating skin perfusion \[[@CR40]--[@CR44]\]. When performing a thermal challenge in different cutaneous regions, Metzler-Wilson et al. \[[@CR40]\] showed that recruitment was higher in the forearm than in the palm. We confirmed this finding in our healthy volunteers.

Different temperature thresholds and heating times have been proposed when performing a thermal challenge \[[@CR28], [@CR29], [@CR38], [@CR40], [@CR41]\]. However, 30 min may be needed to reach the maximal SBF during the test \[[@CR28], [@CR29]\], a period that is too long in critically ill patients who often need rapid changes in therapy. During pilot studies (data not shown), we observed that the best temperature to demonstrate a response was 43 °C. We also observed that we were not able to identify the initial short-lived phase of rapid vasodilation in all patients (this does not mean that the neural stimulus was absent, but just difficult to track with this technology), but when present it had already disappeared at 9 min and its analysis was difficult to standardize (time to peak versus maximum peak versus slope). For these practical reasons, we arbitrarily chose to limit the duration of the thermal challenge to 9 min. Hence, we did not evaluate the maximal recruitment of the skin microcirculation, but a surrogate value (the slope or speed of the microcirculation recruitment) within a reasonable observation period.

Other limitations should also be acknowledged. First, we included a relatively small number of patients, potentially limiting the statistical power of our analyses and possibly accounting for the lack of significant difference in microvascular reactivity between survivors and non-survivors, particularly at 48 h. Moreover, although we found similar results in our two cohorts, external validation of our data is still necessary. Second, although the forearm is a very accessible area in most critically ill patients and has the additional benefit of high potential recruitability with a thermal challenge, studies using different skin locations may also be informative. Further studies are also required to describe the evolution of these alterations over time and their changes with specific therapies (fluid bolus, transfusions, change in vasopressor dose, etc.). Although we focused on mortality as an outcome measure, future studies could also specifically assess relationships with other clinical outcomes, including changes in SOFA scores over time. Third, the presence of fever may represent a confounding factor that should be taken into account; however, the local temperature on the forearm was always less than 37 °C and there was no apparent correlation with the resulting SBF ratio. Fourth, we did not collect data from a control cohort of elderly patients (a factor that can influence the vascular response); however, our control group was designed to provide a picture of the normal physiological response and, more importantly, our main findings are related to the differences between survivors and non-survivors. Fifth, we did not compare the results of the thermal challenge to results from other concomitant measures of the microcirculation. However, our recent observations indicate that VOTs can induce ischemic preconditioning and alter local metabolism \[[@CR19]\], which would need to be taken into account if a skin thermal challenge was performed in the same area. Finally, although it is impossible to extrapolate our skin measurements to other microvascular networks in different organs, the strong association we found with outcomes and the simplicity of this technique makes it attractive for future research.

Conclusion {#Sec11}
==========

SLD with a thermal challenge is a technique that allows simple, noninvasive evaluation of skin microcirculatory reactivity. Using this technique, we have demonstrated that reactivity of skin microcirculation during a thermal challenge is compromised in patients with circulatory shock, is related to outcome and combination with the APACHE II score can improve its prognostic value.
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===============

 {#Sec12}

**Additional file 1:**Tables S1--S4 and Figures S1--S5.
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